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Introduction
The Hippo pathway is a highly conserved pathway that regu-
lates organ size by directing cell proliferation and apoptosis in 
addition to mediating cell growth, cell fate, and stem cell iden-
tity. The Hippo pathway is regulated by cellular architecture 
and environmental properties and may serve as a sensor of tissue 
structure and mechanical tension as well as regulating cytoskel-
etal dynamics.1,2
The pathway is activated by high cell density, which sub-
sequently suppresses cell proliferation and may induce apop-
tosis.3,4 In mammals, when the pathway is activated, a core 
kinase cascade is activated as follows: MST1/2 kinase interacts 
with and phosphorylates WW45, an adaptor protein. Together, 
this complex phosphorylates and activates LATS1/2, which, 
together with its co-factor MOB1, phosphorylates YAP (or 
TAZ, depending on cell context). Once phosphorylated, YAP 
is sequestered or degraded in the cytoplasm.3,5 Both YAP and 
TAZ, most downstream effectors of the pathway, function as 
transcription co-activators to inhibit apoptosis and promote cell 
proliferation.4,6
LATS1 is a tumor suppressor serine–threonine kinase that 
contains 2 PPxY motifs that are able to bind with high affinity to 
WW domain-containing proteins.7-9 In addition to its role within 
the Hippo pathway, LATS1 also plays a role in regulating the cell 
cycle and apoptosis. LATS1 blocks the G
2
/M transition during 
the cell cycle by modulating levels of Cyclin A and B, thereby, 
arresting cell proliferation and inhibiting growth.7 Additionally, 
LATS1 is localized to the centrosome and involved in spindle 
formation during mitosis. Dysfunction of this important process 
can lead to genetic instability, irregular cellular segregation, and 
chromosomal abnormalities. Moreover, LATS1 was found to 
induce apoptosis and, in certain cell lines, upregulate pro-apop-
totic genes such as p53 and Bax in response to extensive DNA 
damage, UV irradiation, chemotherapeutics, oncogenic activa-
tion, and growth factor withdrawal. These functions require the 
kinase activity of the protein. Thus, LATS1 serves as a tumor 
suppressor through several different mechanisms that negatively 
regulate tumor development.9-11
Downregulation of LATS1/2 has been shown in human 
sarcomas, ovarian sarcomas, breast cancers, astrocytomas, reti-
noblastomas, and acute lymphoblastic leukemia.12-14 Several 
oncogenic micro-RNAs have also been implicated in the regula-
tion of LATS1/2 and are overexpressed in some types of cancer, 
such as AGS human gastric15 and testicular cancers.11 Recently, it 
was reported that LATS1 is regulated at the protein level through 
ubiquitin-mediated degradation.16-18 Thus, it could be speculated 
that lower levels of LATS1/2 directly increase the oncogenic 
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proper regulation of cell proliferation, cell apoptosis, and cell death are vital for the development and survival of liv-
ing organisms. Failure or dysfunction of any of these processes can have devastating effects, including cancer. the Hippo 
pathway, first discovered in Drosophila, has been found to be a major growth-regulatory signaling pathway that controls 
these crucial processes and has been implicated in cell-progress regulation and organ size determination. Abnormal reg-
ulation of this pathway has been found in several cancer types. However, the mechanisms that regulate the pathway and 
its core members yet have to be elucidated. one of the main core components of this pathway is LAtS1, a serine/threo-
nine kinase. therefore, understanding how LAtS1 activity is regulated is expected to shed light on new mechanisms that 
regulate the Hippo pathway. In the current work, we identified several potential LAtS1 regulators and proved that NeDD4 
e3 ubiquitin ligase controls LAtS1 stability. We demonstrate that NeDD4 directly interacts with LAtS1, leading to ubiqui-
tination and decreased levels of LAtS1 and, thus, increased YAp localization in the nucleus, which subsequently increases 
the transcriptional activity of YAp. As such, we show that NeDD4 acts as an additional regulator of the Hippo pathway on 
the protein level via interactions between WW domain-containing and ppxY motif-containing proteins. these findings 
might be applied in the development of new therapeutic approaches through the activation of LAtS1.
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nuclear activity of YAP, which might be responsible for the 
advancement of many of the abovementioned cancers.
NEDD4 is an E3 ubiquitin ligase with a HECT catalytic 
domain and 4 WW domains and is involved in ubiquitin-
dependent protein degradation, protein trafficking, and nuclear 
localization of multiple proteins. It has a strong affinity for pro-
line-rich proteins, and many of its substrates carry PY (proline-
tyrosine, PPxY) motifs. It is part of the NEDD4-like family 
of E3 ubiquitin ligase proteins, which also include WWP1/2, 
Smurf1/2, NEDDL1/2, NEDD4L, and ITCH.19,20 NEDD4 was 
first discovered as a developmentally regulated gene in the mouse 
central nervous system and was found to target the epithelial 
sodium channel. Yet many more substrates for this ligase were 
subsequently discovered.21 NEDD4 is involved in several differ-
ent pathways and regulates many important proteins, of which 
several are linked to cancer development.22-26 For example, over-
expression of NEDD4 has been linked to cancers of the prostate, 
bladder, and stomach.19 In the current work, we present addi-
tional evidence of the pro-oncogenic function of NEDD4. We 
identified NEDD4 as a negative regulator of the Hippo tumor 
suppressor pathway via its targeting one of the pathway’s main 
tumor suppressor core kinases, LATS1.
Results
LATS1 is a target of WW domain interaction
We recently reported that the E3-ubiquitin ligase ITCH phys-
ically and functionally regulate LATS1 protein levels and func-
tion.18 We therefore assumed that other WW domain-containing 
proteins might regulate LATS1 function, thereby controlling 
the Hippo pathway. Using a commercial WW domain peptide 
array, we screened for WW domain-containing proteins that are 
able to interact with LATS1. As shown in Figure 1, we detected 
YAP, TAZ, and ITCH as known, previously reported partners 
of LATS1 (Fig. 1A–D). Interestingly, this array showed several 
new WW domain-containing proteins with specific interaction 
with LATS1 (Fig. 1). For example, WW domains 2, 3, and 4 
of NEDD4 bound LATS1 with high affinity (Fig. 1A, row B, 
lines 7–12). By contrast, the WW1 domain of NEDD4 failed 
to interact with LATS1 (Fig. 1A, row B, lines 5–6), suggesting 
a differential binding of NEDD4’s WW domains with LATS1. 
Similarly, WW domains of WWP1 interacted with high affin-
ity to LATS1 (Fig. 1A, row A, lines 9–16). By contrast, the 
WW domains of SMURF1/2, members of the NEDD4-like 
family proteins, did not show high-affinity interactions with 
LATS1 (Fig. 1A, row A, lines 1–8). In another example, the 
WW1 domain of WWOX (Fig. 1C, row D, lines 5 and 6), the 
main interacting WW domain of WWOX,27,28 interacted with 
higher affinity with LATS1 as compared with its WW2 domain 
(Fig. 1C, row D, lines 7 and 8). These findings further indicate 
that LATS1, a key component of the Hippo pathway, is a target 
of specific WW domain interactions, and that these interactions 
might regulate the Hippo pathway.
NEDD4 interacts with LATS1 via its PPxY motif
Since LATS1 protein levels seem to be tightly regulated by E3 
ubiquitin ligases,16-18 we aimed to test whether the E3 ubiquitin 
ligase NEDD4 is also capable of mediating LATS1 degradation 
and modulating the Hippo pathway signaling. To confirm the 
physical interaction between NEDD4 and LATS1, we performed 
an immunoprecipitation (IP) assay between the endogenous pro-
teins using HEK293T cells. Cell lysates were immunoprecipitated 
with polyclonal LATS1 antibody. As a control, we used rabbit 
anti-IgG. Immunoblotting with anti-NEDD4 antibody revealed 
endogenous physical interaction between LATS1 and NEDD4 
(Fig. 1E). To further confirm that NEDD4 does indeed bind 
to LATS1, we did an immunoprecipitation assay between the 
exogenous proteins. HEK293T cells were transfected with Max-
LATS1 and NEDD4. After 24 h, cells were lysed and immuno-
precipitated with an anti-Max antibody. Indeed we found that 
NEDD4 co-immunoprecipitates with LATS1 (Fig. 1F).
To map the interaction between LATS1 and NEDD4, we 
repeated the exogenous interaction between the 2 proteins 
but using a LATS1 plasmid with both PPxY motifs mutated 
(LATS1PY1PY2). As shown in Figure 1F, the interaction between 
LATS1 and NEDD4 was abrogated by PPxY domain mutations, 
indicating that the NEDD4-LATS1 interaction occurs via the 
PPxY motifs on LATS1. Taken together, this data indicates that 
NEDD4, via its WW domains (Fig. 1A), interacts with the PY 
motifs of LATS1 (Fig. 1F).
NEDD4 ubiquitinates LATS1
To analyze the functional significance of the interaction 
between LATS1 and NEDD4, the role of NEDD4 in ubiqui-
tination of LATS1 was analyzed. Extracts of HEK293T cells 
transfected with plasmids expressing HA-UB, Max-LATS1, 
and NEDD4, or the catalytically inactive NEDD4 mutant were 
subjected to immunoprecipitation followed by immunoblotting. 
Expression of NEDD4 increased the ubiquitination of LATS1 
(Fig. 2A lane 2), unlike the inactive mutant of NEDD4 (Fig. 2A 
lane 3), which was still capable of binding LATS1 (data not 
shown).
NEDD4 regulates the stability and half-life of LATS1 and 
modulates YAP phosphorylation
To determine whether NEDD4-mediated ubiquitination 
of LATS1 promotes LATS1 degradation, we measured steady-
state levels of LATS1 in the presence and absence of NEDD4. 
Expression of wild-type, but not mutant NEDD4, decreased the 
protein level of wild-type LATS1 (Fig. 2B) but not LATS1PY1,2 
(Fig. 2C).
To prove that the NEDD4-dependent reduction in LATS1 
protein was a result of increased degradation, we analyzed the 
half-life of LATS1 in the presence or absence of NEDD4 using 
the protein synthesis inhibitor, cycloheximide. Expression of 
NEDD4 led to a decrease in the protein level of LATS1 (Fig. 2D).
Since LATS1 interacts with and phosphorylates YAP (the 
most downstream effector of the Hippo pathway), we next deter-
mined whether this NEDD4-dependent degradation of LATS1 
affects YAP phosphorylation using an antibody that recognizes 
the phosphorylated serine 127 (S127) on YAP. Indeed, our results 
demonstrate that decreased levels of LATS1, brought about by 
NEDD4 overexpression, is accompanied by decreased phos-
pho-YAP levels (Fig. 2D). These results suggest that NEDD4-
mediated degradation of LATS1 might affect Hippo signaling.
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Because most cellular protein degradation is mediated by the 
proteasomal pathway, we treated HEK293T cells expressing Max-
LATS1 and NEDD4 with increasing amounts of the proteasome 
inhibitor MG-132 and determined the protein level of LATS1 by 
western blot. As shown in Figure 2E, treatment with MG132 led 
to increased protein levels of Max-LATS1 in a dose-dependent 
manner, whereas treatment with the lysosomal inhibitor, bafilo-
mycin, had no effect on LATS1 levels (Fig. 2F). Altogether, these 
results indicate that NEDD4 promotes the ubiquitin-dependent 
proteasomal degradation of LATS1.
NEDD4-mediated degradation of LATS1 leads to accumu-
lation of nuclear YAP
Since YAP localization has been shown to be associated with 
LATS1-mediated phosphorylation of S127, we next determined 
whether NEDD4 might affect YAP subcellular localization. GFP-
tagged LATS1 (EGFP-LATS1), pDsRed-YAP2 (Red-YAP2), and 
NEDD4 or mutant NEDD4 were coexpressed in HeLa cells 
and subcellular localization of NEDD4, LATS1, and YAP was 
monitored using confocal microscopy (Fig. 3). Co-expression of 
EGFP-LATS1 and Red-YAP2 showed diffuse and mostly cyto-
plasmic YAP2 (Fig. 3B). In contrast, coexpression of NEDD4 
enhances the localization of LATS1 into cytoplasmic vesicles and 
the nuclear localization of YAP2 (Fig. 3C).
NEDD4 increases YAP transcriptional transactivation 
function
YAP functions as a co-activator of the TEAD transcription 
factors.3,4 Since our data suggest that NEDD4 overexpression may 
enhance YAP nuclear localization (Fig. 3), we decided to investi-
gate if NEDD4 can affect YAP transactivation function of TEAD. 
To this end, we transfected a TEAD4-LUC reporter together with 
YAP2 in HEK293T cells in the presence or absence of NEDD4. 
Upon overexpressing YAP2 with TEAD4 and TEAD4-LUC 
reporter, the reporter activity was induced by 20-fold (Fig. 4). 
In contrast, coexpression of YAP with LATS1 reduced TEAD 
transactivation to 11-fold. Interestingly, this attenuation was res-
cued when NEDD4 was co-expressed with LATS1 and YAP. To 
further confirm the specificity in this assay, we used a mutant 
NEDD4 that was unable to degrade LATS1, and a mutant LATS1 
Figure 1. physical interaction between LAtS1 and NeDD4. (A and C), binding pattern of different WW domain containing proteins to LAtS1 using com-
mercial WW domain arrays (panomics). B&D the key for protein WW domains imprinted on WW domain arrays 1 and 2,  respectively. (E) endogenous 
LAtS1-NeDD4 interaction. HeK293t cells lysates were immunoprecipitated (Ip) with anti-LAtS1 and analyzed by immunoblotting (IB) using anti-NeDD4. 
Cells were pretreated with MG132 for 4 h. Anti-IgG was used as a negative control. (F) NeDD4 forms a complex with LAtS1 in vivo. HeK293t cells were 
cotransfected with either wild-type or mutant Max-LAtS1 and NeDD4. Cell lysates were immunoprecipitated with anti-MAX antibodies. the immuno-
precipitates were analyzed by immunoblotting as indicated. Lysates were also run and blotted to ensure successful transfection of the cells.
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(PY1PY2) that was unable to interact with NEDD4 as controls. 
Upon using the mutant forms of LATS1, the reporter activity was 
not affected as we observed when using wild-type LATS1. In con-
trast, when we used the mutant form of NEDD4, the reporter 
activity was significantly attenuated and was comparable to what 
was obtained upon overexpressing wild type LATS1. These results 
confirm that NEDD4 increases YAP transcriptional co-activa-
tion, at least in part, by downregulating LATS1 levels.
Discussion
The Hippo pathway is an emerging signaling cascade that 
plays pivotal roles in regulating organ size, stem cell pluripotency, 
and tumorigenesis.4,14,29 Protein–protein interactions are a major 
mediator of the Hippo pathway regulation and activation.5,6 
While there are several modular domains present among the vari-
ous players within the pathway, the WW domain clearly stands 
out. Indeed, core cascade proteins, upstream regulators, as well 
as downstream effectors of the pathway were shown to modify 
the pathway outcomes by involvement of WW domain interac-
tions.18,30-33 To further identify the role of other WW domain 
containing proteins in regulating the pathway, we searched for 
LATS1-binding partners using WW domain peptide arrays, since 
LATS1 is a master regulator of the Hippo pathway. Previously, we 
identified the E3 ubiquitin ligase ITCH as a negative regulator 
of the Hippo pathway by interacting with and degrading LATS1. 
We further published that due to this ITCH-dependent reduc-
tion in LATS1 levels, YAP accumulates in the nucleus, leading 
to enhanced transcriptional co-activation of YAP target genes, 
enhanced proliferation, survival, tumorigenicity, and epithelial-
to-mesenchymal transition.18 In the current work, we found 
and identified NEDD4 as a novel negative regulator of LATS1. 
We have demonstrated that NEDD4 physically interacts with 
LATS1 through binding of the WW-PPxY domains, leading to 
ubiquitination and degradation of LATS1 in the proteasome. We 
further showed that overexpression of NEDD4 is associated with 
increased YAP translocation into the nucleus and the activation 
of YAP transcriptional transactivation function.
It seems that ITCH and NEDD4 are not the only E3 ligases 
that control LATS1 stability. Our WW peptide arrays suggest 
that additional E3 ligases appear to regulate LATS1 function 
including WWP1, NEDD4L, and NEDD4L1. Consistent with 
these observations, Yeung et al. have recently demonstrated that 
the WWP1 E3 ligase is capable of binding LATS1 and mediating 
Figure 2. NeDD4 induces ubiquitination and affects the steady-state and half-life of LAtS1 protein. (A) NeDD4 ubiquitinates LAtS1 in vivo. HeK293t cells 
were transfected with the indicated plasmids. After 24 h, cells were treated with 20 μmol/L MG132 for 4 h. Lysates were prepared (B) and Ip with anti-Max 
and detected with anti-HA antibodies (UB). (B and C) LAtS1 steady-state stability is controlled by NeDD4. HeK293t cells were transiently transfected 
with Max-LAtS1 or LAtS1pY1pY2 (C) and NeDD4. After 24 h, cells were lysed and blotted as indicated. (D) ItCH reduces the half-life of LAtS1. HeK293 
cells were cotransfected with the indicated plasmids. After 24 h, cells were treated with 20 μg/mL cycloheximide (CHX) at the indicated time points and 
analyzed as shown in the figure. (E and F) LAtS1 stability is controlled by the proteasomal pathway. HeK293t cells were transiently transfected with 
Max-LAtS1 and NeDD4. After 24 h cells were treated with MG-132 (E), or bafilomycin [BAF] (F) as indicated for 4 additional hours. equal amounts of total 
lysates were blotted as indicated. GApDH, glyceraldehyde-3-phosphate dehydrogenase was always used as a protein loading control. Numbers under 
the blots represent the relative expression of LAtS1 protein after correction with the loading control GApDH expression levels.
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its degradation.16 This WWP1-mediated LATS1 degradation was 
shown to affect cell proliferation in breast cancer cells. Although 
in this article,16 the authors were able to show that, like WWP1, 
NEDD4 overexpression reduces LATS1 protein levels, they 
failed to show that NEDD4 knockdown by siRNA is able to 
increase the endogenous levels of LATS1. This could likely be 
related to the cell type that was used, as the endogenous levels of 
both NEDD4 and LATS1 are much higher than those of WWP1 
and ITCH, which might make it difficult to sufficiently deplete 
NEDD4, or to increase the levels of LATS1. Nevertheless, our 
data clearly demonstrate that NEDD4 is capable of modulating 
LATS1 function in vivo.
Although our data suggest that NEDD4 might have an 
oncogenic function by deregulating the Hippo tumor suppres-
sor pathway, NEDD4 function seems to be complex in this 
respect. On one hand, it has been shown that NEDD4 nega-
tively regulates the function of different tumor suppressor genes, 
such as the tumor suppressor PTEN and the anti-angiogenic 
protein Thrombospondin-1, through which NEDD4 enhances 
tumorigenesis and tumor progression.22,23,25 On the other hand, 
NEDD4 negatively regulates the oncogenic IGF-R signaling 
pathway19,34 as well as the pro-angiogenic factor, VEGF,19,26 and 
thus suppresses tumor growth and progression. Since NEDD4 
regulates the stability of several proteins, we cannot exclude the 
possibility that other proteins could also contribute to the pheno-
types observed in our study.
Previous studies have showed that LATS1 suppresses tumor 
cell growth by interacting with 2 WW domain proteins, YAP and 
TAZ, via its PY motifs.4,35 Our findings shed light on other WW 
domain proteins that might bind LATS1, including NEDD4 and 
WWOX.36,37 It is therefore possible that under physiological con-
ditions, expression of ITCH, NEDD4, and WWP1 may com-
pete with YAP and TAZ for LATS1 binding to control the levels 
of LATS1 tumor suppressor. Developing strategies that specifi-
cally target these E3 ligases, including NEDD4, or disrupt their 
interaction with LATS1 in cancer cells to activate LATS1 may be 
a useful approach for successful cancer therapy.
In conclusion, our study has identified the NEDD4 E3 ligase 
as a novel negative regulator of LATS1 tumor suppressor stabil-
ity. Further characterization of the functional interactions and 
examination of the correlations in clinical samples will provide 
useful information for future targeting of the NEDD4-LATS1 
interaction in cancer intervention.
Materials and Methods
Cell culture and transient transfection
HEK293T cells were grown in DMEM, supplemented with 
10% FBS (Gibco), glutamine, and penicillin/streptomycin (Beit-
Haemek). Cells were routinely authenticated, and cell aliquots 
from early passages were used. Transient transfections were 
achieved using Mirus TransLTi (Mirus Bio LLC).
WW domain arrays
WW Domain Array Kit from Panomics (Panomics, Inc) was 
used according to manufacturer instructions with slight modifi-
cations. In brief, HEK293T cells (10 cm plates) were transiently 
transfected with HA-LATS1. Forty-eight hours post-transfection, 
lysates of plates were collected and incubated with pre-washed 
and blocked array membranes over night at 4 °C with slight shak-
ing. Membranes were washed 3 times with 1× wash buffer for 
10 min/each at room temperature. Membranes were then blot-
ted with anti-HA HRP antibody (Roche Applied Science) and 
detected with ECL.
Immunoprecipitation and immunoblot analysis
Four hours prior to cell lysis, cells were treated with 
20 μmol/L of MG132 (Sigma Aldrich). Cells were lysed by using 
Nonidet P-40 lysis buffer containing 50 mmol/L Tris (pH 7.5), 
150 mmol/L NaCl, 10% glycerol, 0.5% Nonidet P-40, and prote-
ase inhibitors. Lysates were precleared with mouse IgG, immuno-
precipitations were performed in the same buffer, and lysates were 
washed 4 times with the same buffer containing 0.1% Nonidet 
P-40. Western blotting was conducted under standard condi-
tions. Antibodies used were monoclonal anti-Omni (sc-7270, 
Sanat Cruz), polyclonal anti-NEDD4 (sc-25508, Santa Cruz), 
polyclonal anti-phospho-YAPS127 (#4911S, Cell Signaling), and 
monoclonal anti-GAPDH (CB-1001, Calbiochem).
In vivo ubiquitination assay
HEK293 cells were cotransfected with HA-UB, Max-LATS1 
with or without NEDD4. After 24 h, cells were treated with 
MG-132 (20 μmol/L, Sigma) for 4 h. Lysates were immunopre-
cipitated using anti-Max antibody, washed 4 times, and immu-
noblotted with anti-HA-HRP (3F10, Roche Applied Science).
Measurement of steady state and half-life of LATS1 protein 
level
HEK293T cells were transfected with Max-LATS1 with or 
without NEDD4. Twenty-four hours posttransfection, cells were 
lysed or treated with the protein synthesis inhibitor cyclohexi-
mide (100 μg/mL, Sigma) for 3 and 6 h. Cell lysates were sub-
jected to immunoblotting.
Immunofluorescence
Cells were seeded on round slide coverslips in 12-well plates. 
Twenty-four hours later, cells were transfected with the expression 
Figure 3. NeDD4 expression is associated with nuclear YAp. HeLa cells 
were cotransfected with eGFp-LAtS1 with DsRed-YAp in the presence or 
absence of NeDD4. the localization of green fluorescent protein (GFp), 
Red-tagged, and NeDD4 was visualized by confocal microscopy using 
60× magnification.
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plasmids. Twenty-four hours posttransfection, cells were fixed in 
3.7% PBS-buffered formaldehyde, permeabilized with 0.05% 
Triton X-100 at room temperature. Cells were then incubated for 
1 h in 10% goat serum (Invitrogen), with primary antibody for 1 
h and with secondary antibody. Alexa Fluor 647 goat anti-rabbit 
IgG (#A21244, Molecular Probes) was used to detect NEDD4. 
Cells were examined by confocal microscopy (Olympus) under 
60× magnification.
Luciferase assay
HEK293 cells seeded in 12-well plates were cotransfected 
with the relevant plasmids together with TEAD4, TEAD-LUC 
reporter, and Renilla luciferase as an internal control. Cells were 
collected 24 h later, and Firefly and Renilla luciferase activities 
were assayed with Dual-Luciferase Assay System (Promega). 
Firefly luciferase activity was normalized to Renilla luciferase 
activity. All experiments were done at least thrice.
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Figure 4. NeDD4 enhances transcriptional co-activation function of YAp. HeK293t were transfected with the indicated plasmids in addition to teAD 
response elements cloned in GAL4 plasmid, teAD transcription factor, and Renilla plasmid as an internal control for transfection efficiency. twenty-four 
hours later cells were lysed and relative luciferase activity was measured. error bars represent standard deviation; P < 0.05.
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